2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021

BACKGROUND: Eravacycline is a fully synthetic, fluorocycline approved for the treatment of complicated intra-abdominal infections (cIAI) in patients ≥18 years of age in Europe, Singapore, Hong Kong, mainland China, the US, and the UK. The purpose of this study was to monitor the in vitro activity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawser, Stephen, Kothari, Nimmi, Monti, Federica, Hodges, Tony, Zappas, Kristie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677103/
http://dx.doi.org/10.1093/ofid/ofad500.1755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677103/
http://dx.doi.org/10.1093/ofid/ofad500.1755

Ejemplares similares